Burgess E: Management of focal segmental glomerulosclerosis: Evidence-based recommendations. Kidney Int. 1999, 55: S26-S32. 10.1046/j.1523-1755.1999.07004.x.
Article
Google Scholar
Benchimol C: Focal segmental glomerulosclerosis: pathogenesis and treatment. Curr Opin Pediatr. 2003, 15: 171-80. 10.1097/00008480-200304000-00006.
Article
PubMed
Google Scholar
Jafar TH, Stark PC, Schmid CH, for the AIPRD Study Group, et al: Angiotensin-converting enzyme inhibition and progression of renal disease. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int. 2001, 60: 1131-40. 10.1046/j.1523-1755.2001.0600031131.x.
Article
CAS
PubMed
Google Scholar
Gansevoort RT, Sluiter WJ, Hemmelder MH, de Zeeuw D, de Jong PE: Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant. 1995, 10: 1963-74.
CAS
PubMed
Google Scholar
Lama G, Luongo I, Piscitelli A, Salsano ME: Enalapril: Antiproteinuric effect in children with nephrotic syndrome. Clin Nephrol. 2000, 53: 432-6.
CAS
PubMed
Google Scholar
McLaughlin K, Jardine AG: Angiotensin converting enzyme inhibitors and angiotensin receptor (AT1) antagonists: Either or both for primary renal disease?. Nephrol Dial Transplant. 1999, 14: 25-8. 10.1093/ndt/14.1.25.
Article
CAS
PubMed
Google Scholar
Milliner DS, Morgenstern BZ: Angiotensin converting enzyme inhibitors for reduction of proteinuria in children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 1991, 5: 587-90. 10.1007/BF00856646.
Article
CAS
PubMed
Google Scholar
Navis G, de Zeeuw D, de John PE: ACE-inhibitors: Panacea for progressive renal disease?. Lancet. 1997, 349: 1852-3. 10.1016/S0140-6736(97)22026-X.
Article
CAS
PubMed
Google Scholar
Proesmans W, Van Wambeke I, Van Dyck M: Long-term therapy with enalapril in patients with nephrotic-range proteinuria. Pediatr Nephrol. 1996, 10: 587-9. 10.1007/s004670050166.
Article
CAS
PubMed
Google Scholar
Stiles KP, Abbott KC, Welch PG, Yuan CM: Effects of angiotensin-converting enzyme inhibitor and steroid therapy on proteinuria in FSGS: A retrospective study in a single clinic. Clin Nephrol. 2001, 56: 89-95.
CAS
PubMed
Google Scholar
Russo D, Minutolo R, Pisani A, Esposito R, Signoriello G, Andreucci M, Balletta MM: Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis. 2001, 38: 18-25. 10.1053/ajkd.2001.25176.
Article
CAS
PubMed
Google Scholar
Woo KT, Lau YK, Wong KS, Chiang GS: ACEi/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephritis. Kidney Int. 2000, 58: 2485-91. 10.1046/j.1523-1755.2000.00432.x.
Article
CAS
PubMed
Google Scholar
Fried L, Orchard TJ, Kasiske BL, for the Lipids and renal Disease Progression Meta-Analysis Study Group: effect of lipoid reduction on progression of renal disease: A meta-analysis. Kidney Int. 2001, 59: 260-9. 10.1046/j.1523-1755.2001.00487.x.
Article
CAS
PubMed
Google Scholar
Schieppati A, Remuzzi G: the future of renoprotection: frustration and promises. Kidney Int. 2003, 63: 1947-55. 10.1046/j.1523-1755.2003.00340.x.
Article
Google Scholar
Brenner BM: Retarding the progression of renal disease. Kidney Int. 2003, 63: 370-8. 10.1046/j.1523-1755.2003.t01-2-00052.x.
Article
Google Scholar
Zoja C, Corna D, Camozzi D, Cattaneo D, et al: How to fully protect the kidney in a more severe model of progressive nephropathy: a multidrug approach. J Am Soc Nephrol. 2002, 13: 2898-908. 10.1097/01.ASN.0000034912.55186.EC.
Article
CAS
PubMed
Google Scholar
Hebert LA, Wilmer WA, Falkenhain ME, Ladson-Wofford SE, Nahman S, Rovin BH: Renoprotection: One or many therapies?. Kidney Int. 2001, 59: 1211-1226. 10.1046/j.1523-1755.2001.0590041211.x.
Article
CAS
PubMed
Google Scholar
McCarthy ET, Sharma R, Sharma M, Li JZ, Ge XL, Dileepan KN, Savin VJ: TNF-alpha increases albumin permeability of isolated rat glomeruli through the generation of superoxide. J Am Soc Nephrol. 1998, 9: 433-8.
CAS
PubMed
Google Scholar
Gertzberg N, Neumann P, Rizzo V, Johnson A: NAD(P)H oxidase mediates the endothelial barrier dysfunction induced by TNF-α. Am J Physiology. 2004, 286: L37-L48.
CAS
Google Scholar
Wright SC, Zheng H, Zhong J, Torti FM, Larrick JW: Role of protein phosphorylation in TNF-induced apoptosis: phosphatase inhibitors synergize with TNF to activate DNA fragmentation in normal as well as TNF-resistant U937 variants. J Cell Biochem. 1993, 53: 222-33. 10.1002/jcb.240530307.
Article
CAS
PubMed
Google Scholar
Gaur U, Aggerwal BB: Regulation of proliferation, survival, and apoptosis by members of the TNF superfamily. Biochem Pharmacol. 2003, 66: 1403-8. 10.1016/S0006-2952(03)00490-8.
Article
CAS
PubMed
Google Scholar
Ortiz A, Bustos C, Alonso J, Alcazar R, Lopez-Armada MJ, Plaza JJ, Gonzalez E, Egido J: Involvement of tumor necrosis factor-alpha in the pathogenesis of experimental and human glomerulonephritis. Adv Nephrol Necker Hosp. 1995, 24: 53-77.
CAS
PubMed
Google Scholar
Cattran D, Neogi T, McCarthy ET, Savin VJ, Sharma R: Serial estimates of serum permeability activity and clinical correlates in patients with native kidney focal segmental glomerulosclerosis. J Am Soc Nephrol. 2003, 4: 448-53. 10.1097/01.ASN.0000046960.57614.17.
Article
Google Scholar
Savin VJ, Sharma R, Sharma M, et al: Circulating factor increasing glomerular permeability in recurrent focal segmental glomerulosclerosis. N Engl J Med. 1996, 334: 878-883. 10.1056/NEJM199604043341402.
Article
CAS
PubMed
Google Scholar
Savin VJ, McCarthy ET, Sharma R, Sharma M: Galactose binds to focal segmental glomerulosclerosis permeability factor and inhibits its activity. Translational Research. 2008, 151: 288-292. 10.1016/j.trsl.2008.04.001.
Article
CAS
PubMed
Google Scholar
DeSmet E, Rioux JP, Ammann H, Deziel C, Querin S: FSGS permeability factor-associated nephrotic syndrome: remission after oral galactose therapy. Nephrol Dial Transplant. 2009, 24: 2938-40. 10.1093/ndt/gfp278.
Article
CAS
Google Scholar
Meyrier AY: Treatment of focal segmental glomerulosclerosis with immunophilin modulation: when did we stop thinking about pathogenesis?. Kidney Int. 76: 487-491. 10.1038/ki.2009.204.
Cattran DC, Appel GB, Hebert LA, et al: A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int. 1999, 56: 2220-6. 10.1046/j.1523-1755.1999.00778.x.
Article
CAS
PubMed
Google Scholar
Joy MS, Gipson DS, Dike M, Powell L, Thompson A, Vento S, Eddy A, Fogo AB, Kopp JB, Cattran D, Trachtman H: Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group. Clin J Am Soc Nephrol. 2009, 4 (1): 39-47. 10.2215/CJN.02310508. Epub 2008 Dec 10
Article
CAS
PubMed
PubMed Central
Google Scholar
Joy MS, Gipson DS, Powell L, MacHardy J, Jennette JC, Vento S, Pan C, Savin V, eddy A, Fogo AB, Kopp JB, Cattran D, Trachtman H: Phase I trial of adalimumab in focal segmental glomerulosclerosis: II. Report of the FONT (novel therapies for resistant FSGS) study group. Am J Kid Dis. 2010, 55: 50-60. 10.1053/j.ajkd.2009.08.019.
Article
CAS
PubMed
Google Scholar
Peyser A, MacHardy N, Tarapore F, MacHardy J, Powell L, Gipson DS, Savin V, Pan C, Kump T, Vento S, Trachtman H: Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group. BMC Nephrol. 2010, 11: 2-10.1186/1471-2369-11-2.
Article
PubMed
PubMed Central
Google Scholar
Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, Rowland CR: Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004, 2: 12-10.1186/1477-7525-2-12.
Article
PubMed
PubMed Central
Google Scholar
Caridi G, Bertelli R, Carrea A, et al: Prevalence, genetics and clinical features of patients carrying podocin mutations in steroid resistant nonfamilial focal segmental glomerulosclerosis. J Am Soc Nephrol. 2001, 12: 2742-6.
CAS
PubMed
Google Scholar
Pollak MR: The genetic basis of FSGS and steroid-resistant nephrosis. Sem Nephrol. 2003, 23: 141-146. 10.1053/snep.2003.50014.
Article
CAS
Google Scholar
Ruf RG, Lichtenberger A, Karle SM, et al: Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephritic syndrome. J Am Soc Nephrol. 2004, 15: 722-32. 10.1097/01.ASN.0000113552.59155.72.
Article
PubMed
Google Scholar
Caridi G, Bertelli R, DiDuca M, et al: Broadening the spectrum of diseases related to podocin mutations. J Am Soc Nephrol. 2003, 14: 1278-86. 10.1097/01.ASN.0000060578.79050.E0.
Article
CAS
PubMed
Google Scholar
Liu P: Phase II Selection Designs. Handbook of Statistics in Clinical Oncology. Edited by: John Crowley. 2001, Marcel Dekker, Chapter 6: 119-127.
Google Scholar
Simon R, Wittes R, Ellenberg : Randomized phase II clinical trials. Cancer Treatment Rep. 1985, 69: 1375-81.
CAS
Google Scholar
Buyse M: Randomized designs for early trials of new cancer treatments - An overview. Drug Information Journal. 2000, 34: 387-396.
Google Scholar
Korbet SM: Angiotensin antagonists and steroids in the treatment of focal segmental glomerulosclerosis. Semin Nephrol. 2003, 23: 219-28. 10.1053/snep.2003.50020.
Article
CAS
PubMed
Google Scholar
Franceschini N, Hogan SL, Falk RJ: Primum non nocere: Should adults with idiopathic FSGS receive steroids?. Semin Nephrol. 2003, 23: 229-33. 10.1053/snep.2003.50021.
Article
PubMed
Google Scholar
Cattran DC, Rao P: Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. Am J Kid Dis. 1998, 32: 72-9. 10.1053/ajkd.1998.v32.pm9669427.
Article
CAS
PubMed
Google Scholar
Tejani A, Stablein DH: Recurrence of focal segmental glomerulosclerosis posttransplantation: a special report of the North American Pediatric Renal Transplant Cooperative Study. J Am Soc Nephrol. 1992, 2 (12 Suppl): S258-S263.
CAS
PubMed
Google Scholar
Senggutuvan P, Cameron JS, Hartley RB, et al: Recurrence of focal segmental glomerulosclerosis in transplanted kidneys: analysis of incidence and risk factors in 59 allografts. Pediatr Nephrol. 1990, 4: 21-8. 10.1007/BF00858431.
Article
CAS
PubMed
Google Scholar
Huang K, Ferris ME, Andreoni KA, Gipson DS: The differential effect of race among pediatric kidney transplant recipients with focal segmental glomerulosclerosis. Am J Kidney Dis. 2004, 43: 1082-1090. 10.1053/j.ajkd.2004.03.017.
Article
PubMed
Google Scholar
Korbet SM: Treatment of primary focal segmental glomerulosclerosis. Kidney Int. 2002, 62: 2301-10. 10.1046/j.1523-1755.2002.00674.x.
Article
PubMed
Google Scholar
Ponticelli C, Passerini P: Other immunosuppressive agents for focal segmental glomerulosclerosis. Semin Nephrol. 2003, 23: 242-8. 10.1053/snep.2003.50023.
Article
CAS
PubMed
Google Scholar
Selvin E, Bolen S, Yeh HC, Wiley C, Wilson LM, Marinopoulos SS, Feldman L, Vassy J Wilson R, Bass EB, Brancati FL: Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med. 2008, 168 (19): 2070-80. 10.1001/archinte.168.19.2070.
Article
PubMed
PubMed Central
Google Scholar
Phillips PJ, Twigg SM: Oral hypoglycaemics - a review of the evidence. Aust Fam Physician. 2010, 39 (9): 651-3.
PubMed
Google Scholar
Smith RA, Cokkinides V, Eyre HJ: American Cancer Society Guidelines for the Early Detection of Cancer. CA Cancer J Clin. 2003, 53: 27-43. 10.3322/canjclin.53.1.27.
Article
PubMed
Google Scholar